Logo
x

Search

Subscribe Now

Ascendis Pharma

Ascendis Pharma’s Yorvipath Receives the US FDA’s Approval to Treat Hypoparathyroidism

Ascendis Pharma’s Yorvipath Receives the US FDA’s Approval to Treat Hypoparathyroidism

  • August 12, 2024
Ascendis Pharma Receives MHRA Approval for YORVIPATH (Palopegteriparatide) Against Chronic Hypoparathyroidism in Great Britain

Ascendis Pharma Receives MHRA Approval for YORVIPATH (Palopegteriparatide) Against Chronic Hypoparathyroidism in Great Britain

  • April 25, 2024
Ascendis Pharma Receives the EMA’s CHMP Positive Opinion of TransCon PTH (palopegteriparatide) for Chronic Hypoparathyroidism

Ascendis Pharma Receives the EMA’s CHMP Positive Opinion of TransCon PTH (palopegteriparatide) for Chronic Hypoparathyroidism

  • September 15, 2023
Ascendis Pharma Presented One-Year P-III Trial (PaTHway) Results of TransCon PTH for Hypoparathyroidism at ENDO 2023

Ascendis Pharma Presented One-Year P-III Trial (PaTHway) Results of TransCon PTH for Hypoparathyroidism at ENDO 2023

  • June 19, 2023
Ascendis Pharma Reports the US FDA’s Acceptance of NDA for Priority Review of TransCon PTH to Treat Hypoparathyroidism in Adult Patients

Ascendis Pharma Reports the US FDA’s Acceptance of NDA for Priority Review of TransCon PTH to Treat Hypoparathyroidism in Adult Pa...

  • November 1, 2022
Ascendis Pharma Reports Results of TransCon PTH in P-III (PaTHway) Trial for the Treatment of Hypoparathyroidism

Ascendis Pharma Reports Results of TransCon PTH in P-III (PaTHway) Trial for the Treatment of Hypoparathyroidism

  • March 14, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.